C1-KLA

C1-KLA is an experimental peptide-based anticancer agent belonging to the class of mitochondria-disrupting pro-apoptotic peptides that incorporate the well-characterized KLA (KLAKLAK)2 motif. It is designed so that a C1 segment (likely a targeting or cell-penetrating moiety) delivers the KLA domain into tumor cells, where the KLA sequence interacts with and disrupts mitochondrial membranes, triggering apoptosis selectively in cancer cells. Such KLA-based constructs have primarily been explored in preclinical models as targeted cytotoxic payloads intended to enhance antitumor efficacy while reducing off‑target toxicity compared with conventional chemotherapeutics. Publicly available data on C1-KLA are limited, and its precise composition, developer, and clinical development status have not been clearly disclosed.